

Available online freely at www.isisn.org

Bioscience Research

Print ISSN: 1811-9506 Online ISSN: 2218-3973 Journal by Innovative Scientific Information & Services Network



OPEN ACCESS

RESEARCH ARTICLE BIOSCIENCE RESEARCH, 2019 16(3): 2544-2552.

Mesenchymal stem cells different administration routes ameliorative efficacy in acute kidney injury.

Ahmed Nabil^{1*}, Basma H.Othman², E. Mosbah³, M. Sobh⁴ and A. Zaghloul³

¹Department of Biotechnology, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, **Egypt.** ²Medical Experimental Research Center, Faculty of Medicine, Mansoura University, **Egypt.**

³Department of Surgery, Anesthesiology and Radiology, Faculty of Veterinary Medicine, Mansoura University, **Egypt**. ⁴Department of Nephrology & Urology, Faculty of Medicine, Mansoura University, **Egypt**.

*Correspondence: Drnabil_100@psas.bsu.edu.eg Accepted: 16 June. 2019 Published online: 31July. 2019

Mesenchymal stem cells (MSCs) have generated a promising source of all types of cells for cell-based therapy. This study aimed to evaluate the ameliorative effect of MSCs injected different routes in rats with ischemia reperfusion (I/R) induced acute kidney injury. Animals were divided into 3 groups: group (I): Negative control (n=18), group (II): (I/R) untreated :(n=18) and group (III): (I/R) treated with MSCs (36 rats). Group (III) was subdivided into two sub-groups : subgroup (IIIa) was treated with MSCs injected via tail vein; (n=18) and subgroup (IIIb) was treated with MSCs injected sub-capsular; (n=18) .six rats from each group and sub groups were euthanized at day1, days3, and day7 from beginning of the experimental study for histopathological examination and biochemical analysis was performed for serum creatinine, serum monocyte chemo-attractant protein 1 (MCP-1), urinary β-N-Acetyl glucose aminidase (NAG), blood urea nitrogen (BUN), urine creatinine, kidney malondialdehyde (MDA), nitric oxide (NO), annexin V additionally to kidney fibrosis scores for renal tissue were performed in all experimental groups. Our results of revealed that MSCs which injected sub-capsular in rats with renal injury induced ameliorative effects at day 7 through significant decreasing of serum MCP-1, creatinine, BUN, renal MDA, NO, urinary NAG, renal fibrosis score percent of necrotic cells and significantly increases percent of viable renal cells, creatinine clearance compared to rat sub-group treated with MSCs injected via tail vein. It was concluded that subcapsular injected MSCs in rats with (I/R) induced ameliorative effect compared to tail vein injected MSCs.

Keywords: Mesenchymal stem cells, Ischemia - reperfusion, Kidney, Rat

INTRODUCTION

Kidney possess many functions, including blood pressure maintenance, PH regulation and other metabolic processes, such as elimination of nitrogenous wastes and release of endocrine factors. Loss of regional or total blood flow to kidney- induced acute kidney injury (AKI) (Klahr& Morrissey, 2002). Renal warm ischemia reperfusion injury in clinical practice is a consequence of either systemic hypo-perfusion with subsequent circulatory resuscitations or local renal hypo-perfusion following renal transplantation (Dobyan et al., 1980) and surgery of aortic aneurysm related to renal artery (Guinee et al., 1993). Renal ischemia is considered an important mechanism that causes damage to tubular cells in acute renal failure (Dobyan, 1985). Stem cells are undifferentiated cells with significant self-renewal capabilities, able to proliferate and establish daughter cell lines for tissue generation (Nangaku, 2004). MSCs are multipotent cells which great interest to both clinicians and researches for their great potential to enhance tissue engineering, their ease of isolation and manipulability and potential for differentiation into cartilage, bone, fat, muscle, tendon, skin, hematopoitic-supporting stroma and neural tissue (Matsunaga et al., 2005). The bone marrow is the source of MSCs from which many tissues may be obtained (Nakatsuji et al., 1998).

Systemic delivery (intravenous and intraarterial injections) is the most commonly used route for MSCs administration (Nakatsuji et al., direct local 1998). However, injection (intraparenchymal injection) may increase the retention and survival of administrated MSCs to some extent (Hewitson, 2009). Administration of MSCs through renal artery can increase the retention of donor cells and enables them homogeneous dissemination to the damaged kidney in a more physiological manner (Zahran et al., 2016). Therefore the aim of the present study was to evaluate the ameliorative effect of subcapsular and tail vein injected MSCs in rats with induced ischemia reperfusion acute kidney injury.

MATERIALS AND METHODS

Experimental animals:

This study was carried on a total number of 72 male Sprague–Dawley rats (body weight 200–250gm). Rats were bred and housed in standard metallic cages (6 rats per cage) at temperature 20-25°C with an alternating 12 hours light – dark cycle at the animal house of Medical Experimental Research Center (MERC), Faculty of Medicine, Mansoura University. They were acclimatized to the laboratory conditions, fed standard rat chow and water was available ad libitum. The experimental protocol of this work was approved by the Local Ethical Committee, Faculty of Medicine, and Mansoura University.

Mesenchymal stem cells:

Mesenchymal stem cells: Were isolated and prepared at cell culture unit of Medical Experimental Research Center (MERC), Faculty of Medicine, Mansoura University according to (Mcfarlin et al.,2006).

Experimental design:

Rats were allocated into 3 groups. Group (I): Negative control ;(n=18).Group (II): ischemic reperfusion I/R surgically induced as the renal pedicles were clamped with atraumatic vascular clamps for 60 minutes and the rats were subjected to right nephrectomy, then the vascular clamps were released to allow reperfusion to the ischemic kidney untreated ;(n=18). Group (III): ischemic reperfusion surgically induced - treated with MSCs; (n=36). Group (III) was sub-divided into two subgroups as follow :(III.a): ischemic reperfusion surgically induced treated with MSCs injected via tail vein ;(n=18). And (III.b): ischemic reperfusion surgically induced treated with subcapsular injection of MSCs; (n=18). Six rats from each group and sub group were euthanized at day1, day3, and day 7 from beginning of experimental study.

Biochemical analysis:

Blood samples were collected from heart, serum separated and used for determination of serum creatinine according to (Murray, 1984), and blood urea nitrogen (BUN) were estimated according to (Tietz et al., 1995). Serum MCP-1 was estimated according to (De Lemos, 2003) elisa technique. Urine samples were used for determination of urinary creatinine according to (Murray, 1984) in order to calculate creatinine clearance and determination of total protein, also estimation of urinary NAG according to (Vigano, 1981). These parameters were measured using a semi- automated spectrophotometer (Slim Plus, Italy) and (STAT FAX, awareness, USA) Elisa reader.

Annexin V staining technique:

By Annexin V FLUOS staining kit (F. Hoffmann-La Roche, catalog number: 11858777001). Renal cells suspension in a T25 culture flask was incubated for 2 days then the supernatant (apoptotic cells) were collected. Trypsinization of adherent cells from the T25 flask. Washing of the collected cells with PBS then centrifugation. Resuspention of the pellet in phosphate buffered saline.

Finally, addition of 0.5 ml of cells + 100 μ l of incubation buffer + 2 μ l of Annexin + 2 μ l of propidium iodide. Analyze the cells using a flowcytometry without washing the cells (Lakshmanan , 2013).

Tissue Preparation for analysis of MDA, NO:

Frozen kidneys were taken from all experimental rats and tissue homogenates were prepared, according to (Chen et al., 2012), where 0.5 g of kidney homogenization was performed using a solution formed from 5 mL of 0.1 M potassium phosphate buffer (pH 6.5), centrifuged at 3000 rpm/5 min; then, the supernatant was aspirated, collected into separate Eppendorf tubes

and stored at -20°C for further biochemical analysis of renal tissue MDA and NO.

MDA and NO assays in renal tissues:

Renal MDA and NO were determined by using enzymatic colorimetric method. MDA was determined according to (Satoh, 1978) and NO was determined according to (Grees et al., 1982).

Histopathological examination:

Kidneys were perfused in a retrograde fashion through the abdominal aorta using saline 0.9% till complete clearance of the perfusion fluid. Both kidneys in all groups were harvested, cut longitudinally, fixed in 10% neutral buffered formalin and sections were stained with Masson trichrome, for detection of renal fibrosis, (Cohen& Arthur, 1976).

Statistical analysis:

All the data obtained from the experiment were expressed as means ± SEM. Statistical


analysis of data was carried out by software SPSS program package version 17 (SPSS, 2004) using the one-way analysis of variance ANOVA followed by Duncan's Range Test (DMRT) for testing the significant differences between variables. Results were considered significant only at the level of ($p \le 0.05$).

RESULTS

Renal function monitoring:

Serum creatinine and BUN:

Fig. (1&2) Ischemic acute renal injury rats, treated with MSCs via sub-capsular injection showed significant ($p \le 0.05$) decreased serum creatinine at day 3 and significantly ($p \le 0.05$) decreased BUN at day 7 when compared with positive untreated group and animal treated with MSCs via tail vein.



Creatinine

Figure1: Effect of subcapsular and tail vein MSCs therapy on serum creatinine (mg/dl) in acute renal injury model induced by ischemia- reperfusion in rats





Figure. (2): Effect of sub-capsular and tail vein MSCs therapy on serum BUN (mg/dl) in acute renal injury model induced by ischemia- reperfusion in rats.

Creatinine clearance:

Ischemic acute renal injury rats that treated with MSCs via sub-capsular injection showed significant ($p \le 0.05$) increase in creatinine clearance at day 7 compared to untreated and animal treated with MSCs via tail vein Fig. (3).



Creatinine clearance (m l/m in)

Figure 3: Effect of subcapsular and tail vein MSCs therapy on creatinine clearance (mg/dl) in acute renal injury model induced by ischemia- reperfusion in rats.

-Renal (MDA) and nitric oxide (NO) assays in kidney tissue extract:

Renal MDA &NO levels showed significantly ($p \le 0.05$) decreased in rats treated with subcapsular MSCs at day 7 when compared to untreated group and animals treated with MSCs via tail vein injection Fig.(4&5).




Figure 4: Effect of subcapsular and tail vein MSCs therapy on MDA in tissue extract (nmol /g tissue) acute renal injurymodel induced by

ischemia- reperfusion in rats.




Figure 5: Effect of sub-capsular and tail vein MSCs therapy on NO in tissue extract (nmol /g tissue) acute renal injury model induced by ischemia- reperfusion in rats.

Serum monocyte chemoattractant protein 1 (MCP-1) & Urinary β -N-Acetylglucosaminidase (NAG):

Both MSCs treated groups showed significant decreased compared to untreated group after 7 days ($p \le 0.05$), but rats treated with sub-capsular MSCs showed significant decrease ($p \le 0.05$) when compared with tail vein treated group Fig.(8&9).




Figure 8: Effect of sub capsular and tail vein MSCs therapy on MCP-1 inflammatory marker in acute renal injury model induced by ischemia- reperfusion in rats (after 7 days).




Figure 9: Effect of sub capsular and tail vein MSCs therapy on urinary NAG in acute renal injury model induced by ischemia- reperfusion in rats.

Annexin V flow cytometeric analysis:

Cell necrosis showed significant decrease in both MSCs treated groups compared to untreated group after 7 days ($p \le 0.05$), but rats treated with sub-capsular MSCs showed significant decrease ($p \le 0.05$) when compared with tail vein treated group Fig.(7).




Figure 7: Effect of sub capsular and tail vein MSCs therapy on cell necrosis in acute renal injury model induced by ischemia- reperfusion in rats (after 7 days).

Renal fibrosis score:

Revealed that renal fibrosis scores were decreased significantly ($p \le 0.05$) in rats treated with sub-capsular MSCs at day 7 when compared to untreated group and rats treated with MSCs via tail vein injection Fig. (6&10).




Fig. (6): Effect of subcapsular and tail vein MSCs therapy on renal fibrosis in acute renal injury model induced by ischemia- reperfusion in rats.




Fig. (10): Effect of sub capsular and tail vein MSCs therapy on renal fibrosis (Masson trichrome special stain) in acute renal injury model induced by ischemia- reperfusion in rats.
(A : control negative – B: control positive – C : tail vein treated – D : sub capsular treated)

Discussion

Ischemia reperfusion induced acute kidney injury is a common problem among hospitalized patients, mortality rates are high and currently there is no specific medication in use (Waikar et al., 2008). The pathophysiology of I/R-induced AKI is complex and still incompletely understood (Bonventre and Yang, 2011).The damaging effects of renal IR comprise a complex interrelated sequence of events, eventually resulting in both apoptosis and necrosis of the renal cells (Sivarajah et al., 2003).

The emerging field of regenerative medicine is progressing rapidly and supported by a large number of studies demonstrating that stem cells have the capacity to substitute for damaged or lost differentiated cells in various organs and tissues (Zhuo et al., 2001). The anti-inflammatory pattern in MSCs treated animals, indicating the potential of MSCs to modulate (IRI) leading to the earlier regeneration of damaged renal tissue (Chen et al., 2011).Murine rat model was developed to study IRI-induced (AKI) and has many similarities to human IRI-induced AKI was used in all experiments (Kennedy and Erlich, 2008).In rat model the surgical operations can be performed relatively quickly and the duration of ischemia and collection of samples can also be performed at exact time points (Kennedy and Erlich, 2008).

Different experimental studies have provided data using MSCs therapy in various models of I/Rrelated AKI Souidi et al.(2013). Serum creatinine and S-urea levels are the most widely used clinical markers of kidney function Frank et al.,(2012). Creatinine clearance provides a more reliable assessment of renal function Jones et al.(1985). In the present study, the use of sub capsular stem cells was found to be capable of ameliorating renal dysfunction, as demonstrated by improvements of serum creatinine levels, BUN, creatinine clearance. These findings were in agreement with the results of previous study Semedo et al.(2007). In the same trend, Togel et al., 2005) found that MSCs administration either immediately or 24 h after renal ischemia significantly improved renal function.

Urinary NAG has a high molecular mass (>130 kD), so NAG cannot shows glomerular filtration, and only secreted in urine in renal tubules damage (Liangos et al., 2007). So, urinary NAG may be considered as a good indicator for renal tubular damage. In our study, we demonstrated a significant increase in urinary NAG in untreated group compared with the normal group. Also, (Nabil et al., 2018) found that urinary NAG showed significant increase during nephrotoxicity.

MCP - 1 mediates acute ischemic renal injury, so it can be used as a biomarker of acute kidney injury (AKI) (Rice et al., 2018)

In this study, the use of stem cells especially local sub capsular administration was found to ameliorate acute renal injury, as demonstrated by significant decreasing of serum MCP – 1 and urinary NAG These findings were in agreement with the results of previous study (Rice et al., 2018) and (Nabil et al., 2018)

The sudden drop in blood supply and nutrient delivery leads to a cascade of cellular and events. resulting cytoskeleton tissue polarity and disorganization, loss of cell transporter. disfunction of membrane ions Subsequent reperfusion causes a massive production of reactive oxygen species, which are responsible for oxidation of proteins, lipids and nucleic acid in both epithelial and endothelial cells (Salvadori et al., 2015). Results of this study revealed that, the use of sub capsular stem cells showed the more effective role in amelioration oxidative stress and lipid peroxidation in renal tissues of treated sub-group, as reflected by significant decrease in the levels of malodialdehyde and nitric oxide. NO plays an important role in maintaining normal renal function (Faten Zahran et al., 2016). It was found that the reduction of NO production by the NO synthase inhibitor resulted in exacerbation of I / R-induced AKI (Saad et al., 2002; Saleh and El-Demerdash, 2005).

Bone marrow mesenchymal stem cells might fuse with differentiated cells in various adult organs (Rizvi et al., 2006), (Zahran et al., 2014). Cell fusion could be induced between bone marrow-derived cells and renal tubular cells under conditions of renal damage (Held et al., 2006). The obvious and popular candidate for the Bone marrow cell responsible for ameliorating renal damage is the MSC more than haemopoetic stem cells (Humphreys et al., 2008).MSCs have been shown to protect against (I/R) damage and to accelerate the repair process and tubular regeneration in rodents (Herrera et al., 2004). The results of histopathological examination of renal tissues in rats treated with sub-capsular MSCs confirmed results of previous studies (Semedo et al., 2007) (Togel et al., 2005), by significantly lowering renal fibrosis score, lowering of both number of early and late apoptotic cells, lowering necrotic cells and improving the viable cells count.

CONCLUSION

We concluded that MSCs protect kidney

against I/R injury and sub-capsular injection of MSCs in rats with acute kidney injury are more effective than MSCs injected via tail vein. MCSCs induces ameliorative effects at day seven through decreasing serum creatinine, BUN, MCP-1 and urinary NAG also, renal oxidative stress, cellular necrosis and renal fibrosis score and significantly increases creatinine clearance in diseased rat.

CONFLICT OF INTEREST

The authors declared that present study was performed in absence of any conflict of interest.

ACKNOWLEGEMENT

The author(s) received no financial support for the research, authorship, and/or publication of this article.

AUTHOR CONTRIBUTIONS

All authors contributed in this study. Mesenchymal stem cells extraction, flow cytometry and biochemical investigations were responsibility of AN, MS. Surgery, animal modeling and pathological investigations were responsibility of BHO, EM, AZ. All authors contributed in data analysis, paper preparation and revision.

Copyrights: © 2019 @ author (s).

This is an open access article distributed under the terms of the **Creative Commons Attribution License (CC BY 4.0)**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

REFERENCES

- Bonventre, J. V. and Yang, L. (2011): Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121: 4210-21.
- Chen, p., Powell, B. A., Mortimer, M. and. Ke, P.C. (2012): "Adaptive interactions between zinc oxide nanoparticles and Chlorella sp.," Environmental Science & Technology. 46(21):12178–12185.
- Chen, Y.T., Sun, C. K. and Lin, Y. C. (2011): Adipose-derived mesenchymal stem cell protects kidneys against ischemiareperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med. 5: 9-51.

- Cohen, M.D. and Arthur, H. (1976):Masson,strichrome stain in the evaluation of renal biopsies. American J. of clinical pathology. 65(5): 631-643.
- De Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM. Antman EM, McCabe CH, Cannon CP. Braunwald Ε. (2003): Association between plasma levels ofmonocyte chemoattractant protein and long-term clinical outcomes in patients with acute coronary syndromes. Circulation : 107:690-695
- Dobyan, D. C. (1985):Long-term consequences of cis-platinum-induced renal injury: a structural and functional study. Anat Rec. 212:239–245
- Dobyan, D. C., Levi, J., Jacobs, C., Kosek, J and Weiner, M. W.(1980): Mechanism of cisplatinum nephrotoxicity: II. Morphologic observations.JPharmacolExpTher. 213:551– 556.
- Gress, L. C., Wagner, D. A., Glogowski, J. et al., (1982): Analysis of nitrate, nitrite and 15N nitrate in biological fluids. Anal.Biochem. 126:131-138.
- Guinee, D. G, Van Zee, B. and Houghton, D. C.(1985): Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer. 71:4050–4054.
- Held, P. K., Al-Dhalimy, M. (2006). "In vivo genetic selection of renal proximal tubules." MolTher 13(1): 49-58.
- Herrera, M. B., Bussolati, B. (2004): "Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury." Int J Mol Med 14(6): 1035-1041.
- Humphreys, B. D. Valerius, M. T. (2008). "Intrinsic epithelial cells repair the kidney after injury." Cell Stem Cell. 2(3): 284-291.
- Jones, T. W., Chopra, S., Kaufman, J.S. and Trump, B.F. (1985): Cisdiamminedichloroplatinum-induced acute renal failure in the rat correlation of structural and functional alteration. Lab. Invest. 52: 363-374.
- Kennedy, S.E. andErlich, J. H. (2008): Murine renal ischemia- reperfusion injury. Nephrology. 13: 390- 396.
- Klahr, S and Morrissey, J.(2002):Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol. 283: F861- F75.
- Lakshmanan I, Batra SK. (2013): Protocol for Apoptosis Assay by Flow Cytometry Using Annexin V Staining Method. Bio Protocol; 3(6): e374.
- Liu W, Xu Z, Yang H, Deng Y, Xu B and Wei Y.

(2011) The protective effects of tea polyphenols and schisandrin B on nephrotoxicity of mercuric. Biol Trace Elem Res;143(3):1651-65.

- Matsunaga, Y., Kawai, Y., Kohda, Y. andGemba, M.(2005): Involvement of activation of NADPH oxidase and extracellular signalregulated kinase (ERK) in renal cell injury induced by zinc. J Toxicol Sci. 30:135–144.
- Mohamed M. Elshemy, Ahmed ES AbdEl-mejied, Faten Zahran, Mohamed M. Omran and Ahmed Nabil (2018): DPPD ameliorates renal fibrosis induced by HgCl2, Bioscience Research, volume 15(3): 2416-2425
- Murray, R. L. (1984): Creatinine. Kaplan A et al. ClinChem the C.V. Mosby Co. St Louis. Toronto. Princeton. 1261-126.
- Nakatsuji,S., Yamate, J., and Sakuma, S.(1998): Macrophages, myofibroblasts, and extracellular matrix accumulation in interstitial fibrosis of chronic progressive nephropathy in aged rats. Vet Pathol. 35 352–360.
- Nangaku, M. (2004): Mechanisms of tubulointerstitial injury in the kidney final common pathways to end-stage renal failure. InternMed. 2004;43:9–17.
 - Rice JC, Spence JS, Yetman DL, Safirstein RL (2002): Monocyte chemoattractant protein-1 expression correlates with monocyte infiltration in the post-ischemic kidney. Renal Fail 24: 703–723, 2002
- Rizvi, A. Z., Swain, J. R. et al. (2006): "Bone marrow-derived cells fuse with normal and transformed intestinal stem cells." ProcNatlAcadSci U S A. 103(16): 6321-6325.
- Saad, S. Y.Najjar, T. A., Daba, M. H. and Al-Rikabi, A. C. (2002): Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4methylpyridine. Chemotherapy.48:309–315.
- Saleh, S. and El-Demerdash, E. (2005): Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin. Pharmacol. Toxicol; 97:91–97.
- Salvadori, M., Rosso, G. and Bertoni, E. (2015): Update on ischemia/reperfusion injury in kidney transplantation: pathogenesis and treatment. World j. of transplantation. 5: 52-67.
- Satoh, K. (1978): Serum lipidperoxide in cerebrospinal disorder determined by a new colorimetric method. Clinical Chemical Acta. 90: 37- 43.

- Semedo, P., Wang, P.M., Andreucci, M.A., Cenedeze, V.P.A. (2007): Mesenchymal stem cells ameliorate tissue damages triggered by renal ischemia and reperfusion injury. Transplantation proceeding. 39(2): 421-423.
- Sivarajah, A., Chatterjee, P. K., Patel, N. S. A, et al.(2003):Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. The American Journal of Nephrology. 23(4):267–276.
- Souidi, N., Stolk, M. and Seifert, M. (2013): Ischemia-reperfusion injury: beneficial effect of mesenchymal stromal cells. Current opinion in organ transplantation. 18: 34-43.
- SPSS, P. .C (2004): SPSS for windows release 17 SPSS. Inc. USA.
- Tietz, N. W. et al. (1995):Clinical Guide to Laboratory Tests, 3rd ed AACC.
- Togel, F. et al., (2005): Administered mesenchymal stem cells protect agaist ischemic acute renal failure through differentiation independent mechanisms. Am. J. Physiol. Renal Physiol. 289: 31-42.
- Vigano A, Cavanna G, Capodaglio P, Assael BM and Salmona M. (1981): Methodological and clinical aspects of urinary N-acetylglucosaminidase in pediatric subjects. Biochem Med.;25(1):26–33.
- Waikar, S. S., Liu, K. D. andChertow, G.M. (2008). Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am SocNephrol 3: 844-61.
- Faten Zahran, Ahmed Nabil, Amro El Karef, Ahmed Lotfy, Khaled Mahmoud, Walaa G. Hozayen, Mohamed Sobh (2016) "Effect of Antioxidants and Mesenchymal Stem Cells on Cisplatin Induced Renal Fibrosis in Rats.". Journal of Stem Cell Research & Therapeutics, 1 (4), 1.
- Zahran F, El-Ghareb M, Nabil A (2014). Bone Marrow Derived Mesenchymal Stem Cells As A Therapy for Renal Injury.IJAR.4 (4) 11-16.
- Zahran, F., Nabil, A., El-Karef, A., El-Sherbiny, I. M. and Sobh, M. (2016): Effect of nanoformulated antioxidant on development of renal fibrosis induced by cisplatin. J Stem Cell Res Med 1: doi: 10.15761/JSCRM.1000105.
- Zhuo, W., Liao, L., Xu, T., Wu, W., Yang, S. and Tan, J. (2011): Mesenchymal stem cells ameliorate ischemia-reperfusion-induced renal dysfunction by improving the antioxidant/oxidant balance in the ischemic kidney. UrologiaInternationalis. 86(2):191–

196.